KeyBanc raised the firm’s price target on BrightSpring Health (BTSG) to $60 from $55 and keeps an Overweight rating on the shares. The firm says results were once again impressive, highlighted by a 12% EBITDA beat driven by continued momentum with Specialty Pharmacy. BrightSpring raised EBITDA guide more than the beat, but the outlook still looks conservative to KeyBanc.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Earnings Call Highlights Strong Growth Momentum
- BrightSpring Health price target raised to $60 from $52 at BMO Capital
- BrightSpring Health reports Q1 adjusted EPS 39c, consensus 31c
- BrightSpring Health raises 2026 revenue view to $14.73B-$15.23B
- BrightSpring Health Services, Inc. (BTSG) Q1 Earnings Cheat Sheet